Athena Heart 310 -
The therapy is being tested for those with severe hypertriglyceridemia (sHTG), mixed dyslipidemia, and familial hypercholesterolemia (HoFH/HeFH). š Future Outlook
(often associated with ATHENA trial contexts in heart disease research) is an experimental in vivo CRISPR gene-editing therapy designed to provide a one-time treatment for cardiovascular disease risk factors. It specifically targets the ANGPTL3 gene in the liver to permanently lower high levels of triglycerides (TG) and "bad" LDL cholesterol. š” Key Trial Results (Phase 1) ATHENA HEART 310
ANGPTL3 is a protein that normally inhibits enzymes that clear lipids from the blood. By "turning off" this gene, the body can more effectively remove fats. The therapy is being tested for those with
